Chimeric antigen receptor T-cell therapy after COVID-19 in refractory high-grade B-cell lymphoma.
Hayashino K, Seike K, Fujiwara K, Kondo K, Matsubara C, Terao T, Kitamura W, Kamoi C, Fujiwara H, Asada N, Nishimori H, Ennishi D, Fujii K, Fujii N, Matsuoka KI, Maeda Y.
Hayashino K, et al. Among authors: fujii k.
Int J Hematol. 2024 Apr;119(4):459-464. doi: 10.1007/s12185-024-03711-5. Epub 2024 Feb 13.
Int J Hematol. 2024.
PMID: 38349446
Free PMC article.
She was transferred to our hospital for CAR-T therapy, but developed COVID-19. Her symptoms were mild and she was treated with long-term molnupiravir. On day 28 post-infection, lymphodepleting chemotherapy was restarted after a negative polymerase chain reaction (PCR) test …
She was transferred to our hospital for CAR-T therapy, but developed COVID-19. Her symptoms were mild and she was treated with long-term …